Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant865 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01743950 | A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab | terminated | Phase 2 | 49 | University of Wisconsin, MadisonOTHER | 1 | Mar 25, 2026 |
| clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04574856 | Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492836 | Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma(HipoGBM) | not yet recruiting | N/A | 10 | Hospital do CoracaoOTHER | 0 | Mar 25, 2026 | clinicaltrials |
| NCT02286167 | Glioma Modified Atkins-based Diet in Patients With Glioblastoma(GLAD) | completed | N/A | 25 | Wake Forest University Health SciencesOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05413304 | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | active not recruiting | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05702749 | Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas(VS PREHAB) | recruiting | N/A | 36 | Medical College of WisconsinOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT04924608 | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas(KOMET) | active not recruiting | Phase 3 | 145 | AstraZenecaINDUSTRY | 13 | Mar 23, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07089758 | A Study for Cerebral Open Flow Microperfusion | not yet recruiting | N/A | 6 | Mayo ClinicOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | enrolling by invitation | Phase 1 / Phase 2 | 40 | Xiaorong WuINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03551249 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption | completed | N/A | 20 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04458272 | A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | active not recruiting | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05733572 | Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)(NGF-OPG) | active not recruiting | Phase 2 | 36 | Benedetto FalsiniOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07481721 | IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma(APIC-RG) | not yet recruiting | Phase 1 | 24 | Ming YangOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02115074 | Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas(FLUVABREX) | completed | Phase 1 | 20 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02375841 | Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers | active not recruiting | — | 309 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05577416 | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma(AB-218-IIT-201) | completed | Early Phase 1 | 14 | Melbourne HealthOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06725173 | Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis. | recruiting | — | 100 | University of WashingtonOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma(DUAL-CAR-NK-GB) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05393258 | Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas | completed | N/A | 13 | Washington University School of MedicineOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma(TEMPO) | recruiting | Phase 2 | 118 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05753007 | A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients | terminated | Phase 2 | 2 | Mclean HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472387 | Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas(Andro-iGlio) | not yet recruiting | N/A | 40 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03475186 | Testing Ramipril to Prevent Memory Loss in People With Glioblastoma | completed | Phase 2 | 75 | Wake Forest University Health SciencesOTHER | 2 | Mar 13, 2026 | clinicaltrials |
| NCT03749187 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas(PNOC017) | active not recruiting | Phase 1 | 78 | University of California, San FranciscoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04283669 | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas(NF110) | completed | Phase 2 | 12 | University of Alabama at BirminghamOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07469735 | Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma(VANGUARD) | not yet recruiting | N/A | 10 | Huashan HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471100 | Neuromodulation-Induced Cortical Prehabilitation in High Grade Glioma Near the Motor Pathway: Cortical Plasticity Assessed by Navigated Transcranial Magnetic Stimulation (nTMS) | not yet recruiting | N/A | 63 | Azienda Sanitaria dell'Alto AdigeOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT03257618 | Quality of Life and Neurocognitive Functioning(TEMOIN) | completed | N/A | 26 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | active not recruiting | Phase 1 | 60 | Institut de Recherches Internationales ServierOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04044937 | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms(UC-GlioFET) | completed | Phase 2 | 143 | Thomas HopeOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | recruiting | Phase 1 / Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04716699 | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma | completed | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07461948 | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients | recruiting | Phase 3 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03141021 | Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | recruiting | — | 1,050 | Washington University School of MedicineOTHER | 5 | Mar 9, 2026 | clinicaltrials |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | active not recruiting | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05182905 | AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients | active not recruiting | Early Phase 1 | 97 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05660408 | RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors(RNA PRIME) | active not recruiting | Phase 1 / Phase 2 | 36 | University of FloridaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05859659 | Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE) | recruiting | — | 70,000 | Yaou LiuOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07457307 | Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac(INSIGHT MRL) | not yet recruiting | Phase 1 | 20 | NYU Langone HealthOTHER | 1 | Mar 9, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 27, 2026source: clinicaltrials